Maine Medicine Weekly Update - 03/06/2017 (Plain Text Version)
|
||
In this issue: |
AMA National Advocacy Conference
MMA EVP Gordon Smith and President Charles Pattavina, M.D. attended the AMA's annual National Advocacy Conference in Washington, D.C. last week and met with members of Maine's Congressional Delegation.
The 2017 American Medical Association National Advocacy Conference was held in Washington D.C. Feb. 27 - March 1. MMA President Charles Pattavina, M.D. attended with EVP Gordon Smith. Featuring presentations by Mick Eberling, CEO of Not Impossible Labs and Mark Halperin, Editor, author and political analyst, the conference offered a unique opportunity to be in the nation's capital at a time of great uncertainly but informed somewhat by the President's speech to a joint session of Congress on February 28th. Members of Congress speaking at the conference included Sen. John Barrasso, M.D. (R-Wyoming), Sen. Ron Wyden (D-Oregon) and Congressmen Charlie Dent, Kevin Brady and Joseph Crowley. During the conference, Dr. Pattavina and Mr. Smith were able to meet personally with Senator Collins and King and Congresswoman Pingree. The advocacy message delivered was that repealing the Affordable Care Act should not be done, if at all, until a full replacement reform bill is ready which protects coverage for those individuals covered under existing law and which continues to move the country toward all individuals being covered. We also spoke forcefully against the notion of Medicaid block grants although we ackowledged the need for the states to have more flexibility in using Medicaid dollars. We also articulated that states that did not expand Medicaid eligibility under the ACA should be provided with the federal dollars that were available with expansion. We also discussed the opioid crisis and what is being done in Maine to address it. We also supported repealing the unpopular IPAB provision and noted the importance of the Congress re-authorizing the children's CHIP program by September 1st of this year. Other interesting points that were made by the various speakers and AMA advocacy staff:
BOTTOM LINE |